Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07590986

Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN.

The main questions it aims to answer are:

* Are there T cells in the bone marrow that can recognize MPN cells? * Which targets (antigens) on MPN cells are recognized by these immune cells? * Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies?

Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison.

By providing blood and bone marrow samples, participants will:

* Allow researchers to study immune cells and genetic material from these samples * Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells

Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN.

Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

de Duve Institute, UCLouvain

Brussels, Woluwe, 1200, Belgium

Location status: Recruiting

Location contact

Sophie Lucas, Pr

CONTACT

[email protected]

0032 (0)2 436 23 00

Violaine Havelange

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN.
  • Patients not previously diagnosed with a haematological disease as controls

Exclusion criteria

  • Patients with any other hematological malignancy.

Treatment and study plan

Primary outcomes

  1. Identification of MPN-specific CD8+ T cell clonotypes and corresponding tumor antigens

    Time frame: Throughout the whole study, approximately during 10 years

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Université Catholique de Louvain

Other

Registry information

Important dates

Study start
2026
Primary completion
2036
Study completion
2037
First posted
May 15, 2026
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.